Evotec signs high throughout screening collaboration with Alios BioPharma
Evotec is to collaborate with Alios Biopharma in the area of high throughput screening (HTS).
Evotec is to collaborate with Alios Biopharma in the area of high throughput screening (HTS).
Alios BioPharma is a San Francisco-based biotechnology company involved in developing novel medicines that treat diseases in virology by activating pathways in the innate immune system.
Evotec of Germany will use its proprietary ultra-HTS platform and technology, developed in collaboration with Pfizer, Novartis and GSK, to screen a priority biological target for Alios.
HTS combines an ultra-sensitive detection technology with a miniaturised screening format.
As part of the agreement, Alios will in addition have access to Evotec's small molecule screening library.
No financial details were disclosed.
"Evotec has compiled a small molecule screening library that provides excellent diversity and high quality. This, combined with the company's exceptional HTS technology makes it an ideal partner for screening our important target with the aim of finding high quality hits for our subsequent medicinal chemistry efforts," said Dr Leonid Beigelman, executive vice president of research at Alios.
Dr Mark Ashton, Evotec's EVP, business development, added: We are excited about identifying new hits for Alios" programme and supporting the company in its quest for new treatments for virology diseases."